Universal Beteiligungs und Servicegesellschaft mbH Acquires 51,204 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 560.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,344 shares of the company’s stock after acquiring an additional 51,204 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Kiniksa Pharmaceuticals International worth $2,343,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of KNSA. EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $31,000. USA Financial Formulas acquired a new position in shares of Kiniksa Pharmaceuticals International in the third quarter valued at approximately $32,000. Quantbot Technologies LP acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $43,000. Finally, Farther Finance Advisors LLC increased its position in shares of Kiniksa Pharmaceuticals International by 582.4% during the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock worth $53,000 after acquiring an additional 1,159 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 42,841 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the sale, the chief financial officer directly owned 31,086 shares of the company’s stock, valued at approximately $1,289,758.14. This represents a 57.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Eben Tessari sold 12,470 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $41.24, for a total transaction of $514,262.80. Following the completion of the transaction, the chief operating officer directly owned 22,714 shares of the company’s stock, valued at approximately $936,725.36. This trade represents a 35.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 119,588 shares of company stock worth $4,953,970. Insiders own 53.48% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on KNSA shares. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. The Goldman Sachs Group boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Wedbush lifted their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.33.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $43.96 on Friday. Kiniksa Pharmaceuticals International, plc has a 52-week low of $18.12 and a 52-week high of $45.00. The company has a market cap of $3.33 billion, a P/E ratio of 97.69 and a beta of 0.04. The stock’s 50-day simple moving average is $41.63 and its 200 day simple moving average is $37.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.18) earnings per share. As a group, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.